WARPTECHNEWS · LAB

Home AI Business Tech Archive

Storia: Pfizer Raises Sales Guidance on High Demand for Older Drugs — Warptech Lab News

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Storia in 5 fonti

Pfizer Raises Sales Guidance on High Demand for Older Drugs

(Bloomberg) -- Pfizer Inc. raised the midpoint of its 2026 sales forecast after reporting strong second-quarter demand for older medicines.

Raccontata da

Confronto fonti

5 prospettive sulla stessa storia

AI · summaries

swissinfo.chStai leggendo19 h fa

Pfizer Raises Sales Guidance on High Demand for Older Drugs

(Bloomberg) -- Pfizer Inc. raised the midpoint of its 2026 sales forecast after reporting strong second-quarter demand for older medicines.

Timeline cronologica

martedì 4 agosto 2026·swissinfo.ch
Pfizer Raises Sales Guidance on High Demand for Older Drugs
(Bloomberg) -- Pfizer Inc. raised the midpoint of its 2026 sales forecast after reporting strong second-quarter demand for older medicines.
martedì 4 agosto 2026·cnbc.com
Pfizer tops quarterly estimates, hikes low end of revenue guidance on strength of non-Covid products
Pfizer said it cut its full-year revenue expectation for its Covid products to $4 billion, down from around $5 billion previously.

17 h fa

Pfizer raises sales guidance on high demand for older drugs

Drugmaker plans for another $2.5bn in cost savings as it looks to move beyond post-Covid sales slump

Leggi questa versione → originale

cnbc.com18 h fa

Pfizer tops quarterly estimates, hikes low end of revenue guidance on strength of non-Covid products

Pfizer said it cut its full-year revenue expectation for its Covid products to $4 billion, down from around $5 billion previously.

Leggi questa versione → originale

benzinga.com13 h fa

What's Going on With Pfizer Stock Tuesday? - Pfizer (NYSE:PFE)

Pfizer beat Q2 (EPS 77¢ vs 69¢) and raised FY2026 guidance to $60.5–62.5B. Strategic acquisitions in oncology/obesity signal post-COVID shift; Metsera approval target 2028 exemplifies pivot toward specialty therapeutics and emerging clinical markets.

Leggi questa versione → originale

arabnews.com17 h fa

Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts

GENEVA: Pfizer on Tuesday reported better-than-expected second-quarter results, boosted by strong demand for blood thinner Eliquis, and unveiled plans for an additional $2.5 billion in savings through its ongoing…

Leggi questa versione → originale

martedì 4 agosto 2026·

arabnews.com

Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts

GENEVA: Pfizer on Tuesday reported better-than-expected second-quarter results, boosted by strong demand for blood thinner Eliquis, and unveiled plans for an additional $2.5…

martedì 4 agosto 2026·

irishtimes.com

Pfizer raises sales guidance on high demand for older drugs

Drugmaker plans for another $2.5bn in cost savings as it looks to move beyond post-Covid sales slump

martedì 4 agosto 2026·

benzinga.com

What's Going on With Pfizer Stock Tuesday? - Pfizer (NYSE:PFE)

Pfizer stock rises after beating Q2 estimates and raising its 2026 revenue guidance to up to $62.5B. Get the key earnings takeaways.